GL1X · GenesisL1 explorer

Research workbench

Crystal structure of the Fc fragment of anti-tnfa antibody infliximab (remicade) in a primative orthorhombic crystal form, lot C

Analyse Crystal structure of the Fc fragment of anti-tnfa antibody infliximab… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
6UGY
Type
protein
Length
206 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
UniProt
P0DOX5
Ligands
NAG, MAN, BMA, GAL, FUC, ZN

Structure

x-ray diffraction · 1 distinct chain.

ChainMoleculeTypeResiduesSecondary structureUniProt
A—protein206—P0DOX5

Ligands and binding sites

  • NAG · 2-acetamido-2-deoxy-beta-D-glucopyranose · sugar · 3 copies · chains A
  • MAN · alpha-D-mannopyranose · sugar · 2 copies · chains A
  • BMA · beta-D-mannopyranose · sugar · chains A
  • GAL · beta-D-galactopyranose · sugar · chains A
  • FUC · alpha-L-fucopyranose · sugar · chains A
  • ZN · Zinc ion · metal · 3 copies · chains A
  • ACT · Acetate ion · additive · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Compared structures

  • 6UGY · Crystal structure of the Fc fragment of anti-TNFa antibody infliximab (Remicade) in a… · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.